Probing and modeling decidual natural killer cells in preterm birth
早产中蜕膜自然杀伤细胞的探测和建模
基本信息
- 批准号:10607933
- 负责人:
- 金额:$ 6.97万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-11-01 至 2024-10-31
- 项目状态:已结题
- 来源:
- 关键词:AlloantigenAllogenicAnimal ModelApoptosisBasal PlateBiological AssayBiological ModelsBloodBlood flowCXCL12 geneCatalogsCell CommunicationCell physiologyCellsChemicalsCoculture TechniquesDataDeciduaDecidual CellDecidual Cell ReactionsDevelopmentDiseaseEndometrialEndometriumEnvironmentEquilibriumFetusFibroblastsFirst Pregnancy TrimesterFlow CytometryGalactose Binding LectinGene ExpressionGestational AgeGrowth and Development functionHeterogeneityHumanHypoxiaIL8 geneImmuneImmune systemIndividualInflammatoryIonomycinK562 CellsLabor OnsetLeukocytesLocationMaintenanceMaternal-Fetal ExchangeMeasuresMembraneMethodsModelingNatural Killer CellsNaturePatientsPhenotypePlacentaPlacentationPlayPopulationPregnancyPregnancy OutcomePremature BirthPremature LaborProcessProtocols documentationPublishingResourcesRoleSeriesStagingSurfaceTerm BirthTimeTissuesUterusVascular Endothelial Growth FactorsVascular remodelingWorkbasecytokinecytotoxicitydifferentiation protocolfetalgene functionhealthy pregnancyhuman modelin vitro Modelinduced pluripotent stem cellinsightpathogenperipheral bloodresponsesingle-cell RNA sequencingstem cell differentiationtranscriptometranscriptome sequencingtranscriptomicstrophoblast
项目摘要
Project Summary/Abstract
The human placenta is a semi-allogeneic tissue whose growth and development requires tolerance by the
maternal immune system. How this relationship is compromised in the setting of spontaneous preterm birth
(sPTB) is currently unknown. In a normal pregnancy, placental cells come in close contact with maternal blood
and uterine tissues yet are able to evade immune recognition throughout gestation. During this time, the maternal
immune system maintains a balance of tolerance toward foreign fetal alloantigens while simultaneously staging
a response to potential pathogens at the maternal-fetal interface. The nature of such maternal-fetal cellular
interactions is poorly understood, particularly when it goes awry in the setting of spontaneous preterm birth
(sPTB). The uterine lining, called decidua, is a particularly understudied microenvironment, containing many
maternal immune cells, of which decidual natural killer (dNK) cells are the most abundant. It is at this interface
where placental cells called extravillous trophoblast (EVT) come in close contact with maternal immune cells.
Invasion of the decidua by fetal EVT is required for proper remodeling of the maternal uterine lining, including
vascular remodeling which leads to establishment of maternal blood flow to the placenta. Interactions between
placental EVT and decidual leukocytes, such as dNK, are known to facilitate maternal vascular remodeling by
EVT and limit the extent of EVT invasion into the uterine wall. Indeed, problems in sPTB could result from
inappropriate responses by dNK cells. Unfortunately, dNK function, including dNK-trophoblast crosstalk, is
difficult to study in an ongoing pregnancy, due to lack of access to the decidual compartment, where these
important interactions occur. Additionally, very few studies have characterized dNK at term when the pregnancy
outcome is known. While animal models have offered some insights into these processes, they do not accurately
model human placentation and pregnancy. This proposal aims to functionally and transcriptomically characterize
dNK subpopulation(s) in term, with or without labor, and preterm placenta, then use induced pluripotent stem
cells (iPSC) to model dNK, in the setting of both term and preterm birth. Our team has established optimized
methods for differentiation of iPSC into both peripheral blood NK cells and EVT. We will now optimize a protocol
for iPSC differentiation into decidual NK cells, comparing them directly to primary cells. Successful completion
of this proposal will reveal underlying mechanisms through which abnormal dNK activation contributes
to spontaneous preterm birth, and establish a renewable and manipulatable model of dNK at the human
maternal-fetal interface.
项目总结/摘要
人胎盘是一种半同种异体组织,其生长和发育需要胎盘细胞的耐受性。
母体免疫系统在自发性早产的情况下,这种关系如何受到损害
目前尚不清楚sPTB。在正常妊娠中,胎盘细胞与母体血液密切接触,
而子宫组织在整个妊娠期仍能逃避免疫识别。在此期间,产妇
免疫系统维持对外来胎儿同种异体抗原的耐受平衡,同时分期
对母胎界面潜在病原体的反应这种母胎细胞的性质
相互作用知之甚少,特别是当它在自发性早产的情况下出错时
(sPTB)。子宫内膜,称为蜕膜,是一个特别未被充分研究的微环境,含有许多
母体免疫细胞,其中蜕膜自然杀伤(dNK)细胞是最丰富的。在这个界面上
其中称为绒毛外滋养层(EVT)的胎盘细胞与母体免疫细胞密切接触。
胎儿EVT侵入蜕膜是母体子宫内膜适当重塑所必需的,包括
血管重塑,导致母体血液流向胎盘。之间的相互作用
已知胎盘EVT和蜕膜白细胞,如dNK,通过以下方式促进母体血管重塑:
EVT,并限制EVT侵入子宫壁的程度。事实上,sPTB的问题可能是由于
dNK细胞的不适当反应。不幸的是,dNK功能,包括dNK-滋养层串扰,
难以在正在进行的妊娠中进行研究,因为缺乏进入蜕膜室的途径,
发生了重要的相互作用。此外,很少有研究在妊娠时描述dNK的特征。
结果已知。虽然动物模型为这些过程提供了一些见解,但它们并不准确。
模拟人类胎盘形成和妊娠。该提案旨在从功能和转录组学上表征
足月dNK亚群,有或没有分娩,以及早产胎盘,然后使用诱导多能干细胞
细胞(iPSC)来模拟dNK,在足月和早产的情况下。我们的团队已经建立了优化的
iPSC分化为外周血NK细胞和EVT的方法。我们现在将优化一个协议
对于iPSC分化为蜕膜NK细胞,将其直接与原代细胞进行比较。成功完成
这一提议的结果将揭示异常dNK激活有助于
目的:建立一种可更新的、可操作的人dNK模型,
母胎界面
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Virginia Chu Cheung其他文献
Virginia Chu Cheung的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
HLA-homozygous iPSC-cardiomyocytE Aggregate manufacturing technoLogies for allogenic cell therapy to the heart (HEAL)
HLA-纯合 iPSC-心肌细胞 用于心脏同种异体细胞治疗 (HEAL) 的聚集体制造技术
- 批准号:
10039902 - 财政年份:2022
- 资助金额:
$ 6.97万 - 项目类别:
EU-Funded
Evaluation of the efficacy of LAT1 inhibitor to tumor stroma and immunity in an allogenic mouse model of colon cancer having abundant stroma.
在具有丰富基质的同种异体结肠癌小鼠模型中评估 LAT1 抑制剂对肿瘤基质和免疫的功效。
- 批准号:
21K15925 - 财政年份:2021
- 资助金额:
$ 6.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Mechanism of kidney injury associated with graft-versus-host disease after allogenic stem cell transplantation
同种异体干细胞移植后移植物抗宿主病相关肾损伤的机制
- 批准号:
21K08410 - 财政年份:2021
- 资助金额:
$ 6.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Clarification of the origin and maintenance mechanisms of junctional epithelium and identification of its stem cells using allogenic tooth germ transplantation
阐明交界上皮的起源和维持机制并利用同种异体牙胚移植鉴定其干细胞
- 批准号:
20K21672 - 财政年份:2020
- 资助金额:
$ 6.97万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
The study about the allogenic MSCs transplantation to the cardiac disease models.
同种异体间充质干细胞移植至心脏病模型的研究。
- 批准号:
18K16395 - 财政年份:2018
- 资助金额:
$ 6.97万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Artificial nerves containing allogenic basal lamellae scaffold and bone marrow derived stem cells
含有同种异体基底板层支架和骨髓干细胞的人工神经
- 批准号:
17K10951 - 财政年份:2017
- 资助金额:
$ 6.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Role of HSP90-alpha in preserving immunoprivilege of allogenic mesenchymal stem cells in the ischemic heart
HSP90-α 在保护缺血心脏同种异体间充质干细胞免疫特权中的作用
- 批准号:
370541 - 财政年份:2017
- 资助金额:
$ 6.97万 - 项目类别:
Operating Grants
Attempt to Prefabricate Vascularized Allogenic Bone in Recipient -Use of Cultured Bone Marrow Cells-
尝试在受者体内预制血管化的同种异体骨 - 使用培养的骨髓细胞 -
- 批准号:
16K10863 - 财政年份:2016
- 资助金额:
$ 6.97万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Allogenic micobiota-reconstitution (AMR) for the treatment of patients with diarhea-predominant irritable bowel syndrome (IBS-D) - the AMIRA trial
同种异体微生物群重建 (AMR) 用于治疗腹泻型肠易激综合征 (IBS-D) 患者 - AMIRA 试验
- 批准号:
276706135 - 财政年份:2015
- 资助金额:
$ 6.97万 - 项目类别:
Clinical Trials
Induction of thyme epithelial cells from iPS cells and application to allogenic transplantation
iPS细胞诱导百里香上皮细胞及其在同种异体移植中的应用
- 批准号:
15H04915 - 财政年份:2015
- 资助金额:
$ 6.97万 - 项目类别:
Grant-in-Aid for Scientific Research (B)